

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



PAD4 (human, recombinant; His- and GST-tagged)

Item No. 25915

Overview and Properties

Synonyms: PADI4, PADI5, Peptidylarginine Deiminase 4, Protein Arginine Deiminase Type 4,

Protein Arginine Deiminase Type IV

Source: Active recombinant N-terminal His-GST-tagged PAD4 expressed in E. coli

Amino Acids: 2-663 (full length)

Uniprot No.: Q9UM07 Molecular Weight: 103.2 kDa

Storage: -80°C (as supplied)

Stability: ≥1 year

batch specific (≥80% estimated by SDS-PAGE) **Purity:**

Supplied in: 50 mM HEPES, pH 8.0, 300 mM sodium chloride, 1mM DTT, and 10% glycerol

Protein

Concentration: batch specific Activity: batch specific Specific Activity: batch specific


One unit is defined as the amount of enyme required to produce 1 nmol of $\mathrm{NH_4}^+$ per **Unit Definition:**

minute at 37°C in 50 mM HEPES, pH 8.0, containing 10 mM calcium chloride, 5 mM


DTT, and 2 mM N-α-Benzoyl-L-Arginine Ethyl Ester (BAEE).

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Lane 2: PAD4 (His- and GST-tagged; 4 µg) Lane 3: PAD4 (His- and GST-tagged; 2 µg)



PAD4 activity was determined using Cayman's PAD4 Inhibitor Screening Assay Kit (Item No. 700560) with 0.25 µg PAD4 and 2 mM BAEE substrate.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Protein arginine deiminase 4 (PAD4) catalyzes the conversion of arginine residues to citrulline within cellular protein substrates, resulting in the loss of a positive charge, which can alter protein structure and/or function. It is expressed in neutrophils, as well as a variety of tissues, including the brain, liver, lung, and kidney. 1-3 PAD4 has a key role in NETosis, a lytic form of cell death characterized by the release of neutrophil extracellular traps (NETs). Upon neutrophil activation, PAD4 translocates to the nucleus where it citrullinates histones, initiating chromatin decondensation and the release of NETs.2-4,5 Neutrophils isolated from Pad4-/- mice exhibit decreased citrullination of histone H3 under both basal and LPS-stimulated conditions and are defective for NET formation in response to stimulation with LPS, phorbol 12-myristate 13-acetate (PMA; Item No. 10008014), or hydrogen peroxide.⁴ Pad4-⁷ mice exhibit larger lesions than wild-type mice in a model of necrotizing fasciitis induced by M1 group A S. pyogenes lacking the extracellular DNase Sda1. Pad4-deficient mice also exhibit reduced infarct size in a model of myocardial ischemia-reperfusion injury and reduced tumor growth in a Lewis lung carcinoma model.^{2,6} Serum PAD4 autoantibodies have been found in patients with rheumatoid arthritis and are associated with disease severity. Cayman's PAD4 (human, recombinant; His- and GST-tagged) protein can be used for enzyme activity assays. This protein contains two types of affinity tags, His and GST, that allow for flexibility in the removal of PAD4 following citrullination reactions and an enterokinase cleavage site that facilitates removal of both the His and GST tags.

References

- 1. van Beers, J.J.B.C., Zendman, A.J.W., Raijmakers, R., et al. Peptidylarginine deiminase expression and activity in PAD2 knock-out and PAD4-low mice. *Biochimie* **95(2)**, 299-308 (2013).
- 2. Demers, M., Wong, S.L., Martinod, K., et al. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology 5(5), e1134073 (2016).
- 3. Jones, J.E., Causey, C.P., Knuckley, B., et al. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. *Curr. Opin. Drug Discov. Devel.* **12(5)**, 616-627 (2009).
- 4. Li, P., Li, M., Lindberg, M.R., et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207(9), 1853-1862 (2010).
- Thiam, H.R., Wong, S.L., Qiu, R., et al. NETosis proceeds by cytoskeleton and endomembrane disassembly and PAD4-mediated chromatin decondensation and nuclear envelope rupture. Proc. Natl. Acad. Sci. USA 117(13), 7326-7337 (2020).
- Savchenko, A.S., Borissoff, J.I., Martinod, K., et al. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 123(1), 141-148 (2014).
- 7. Halvorsen, E.H., Pollmann, S., Gilboe, I.M., et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann. Rheum. Dis. 67(3), 414-417 (2008).